Understanding the glioblastoma tumor biology to optimize photodynamic therapy: From molecular to cellular events

J Neurosci Res. 2021 Apr;99(4):1024-1047. doi: 10.1002/jnr.24776. Epub 2020 Dec 28.

Abstract

Photodynamic therapy (PDT) has recently gained attention as an alternative treatment of malignant gliomas. Glioblastoma (GBM) is the most prevalent within tumors of the central nervous system (CNS). Conventional treatments for this CNS tumor include surgery, radiation, and chemotherapy. Surgery is still being considered as the treatment of choice. Even so, the poor prognosis and/or recurrence of the disease after applying any of these treatments highlight the urgency of exploring new therapies and/or improving existing ones to achieve the definitive eradication of tumor masses and remaining cells. PDT is a therapeutic modality that involves the destruction of tumor cells by reactive oxygen species induced by light, which were previously treated with a photosensitizing agent. However, in recent years, its experimental application has expanded to other effects that could improve overall performance against GBM. In the current review, we revisit the main advances of PDT for GBM management and also, the recent mechanistic insights about cellular and molecular aspects related to tumoral resistance to PDT of GBM.

Keywords: blood-brain barrier; glioblastoma; photodynamic therapy; resistance mechanisms; tumor microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Apoptosis
  • Blood-Brain Barrier
  • Central Nervous System / pathology
  • Drug Resistance, Neoplasm
  • Glioblastoma / metabolism*
  • Glioblastoma / therapy*
  • Humans
  • Neoplasm Invasiveness
  • Oxidative Stress
  • Photochemotherapy / methods*
  • Reactive Oxygen Species / therapeutic use*
  • Tumor Microenvironment

Substances

  • Reactive Oxygen Species